Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 405 Brain Neoplasms 163 Glioma 159 Gliosarcoma 128 Astrocytoma 115 Central Nervous System Neoplasms 110 Oligodendroglioma 74 Neuroblastoma 44 Medulloblastoma 33 Ependymoma 26 Recurrence 23 Neoplasms 19 Neoplasm Metastasis 16 Diffuse Intrinsic Pontine Glioma 15 Choroid Plexus Neoplasms 13 Optic Nerve Glioma 11 Melanoma 11 Spinal Cord Neoplasms 10 Rhabdoid Tumor 10 Lymphoma 9 Familial ependymoma 9 Rhabdomyosarcoma 8 Osteosarcoma 8 Neuroectodermal Tumors, Primitive 8 Breast Neoplasms 8 Sarcoma, Ewing 6 Sarcoma 6 Pinealoma 6 Neuroectodermal Tumors, Primitive, Peripheral 6 Glioma, Subependymal 6

Interventions

pembrolizumab 2 fluciclovine F-18 2 neratinib 1 alovudine 1 Temozolomide 1 Oncolytic Virotherapy 1 Magnetic Resonance Spectroscopy 1 Interleukin-15 1 Cyclophosphamide 1 Antibodies, Monoclonal 1 ABT-414 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Disease × Temozolomide × CNS × Clear all

NCT00660283 2010-01-20

KARE003

Kentuckiana Cancer Institute

Phase 2 Unknown

Disease, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡